Company profile

Ticker
BMY+
Exchange
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
220790350

Calendar

25 Apr 19
18 Jun 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 5.92B 5.97B 5.69B 5.7B
Net income 1.71B 1.16B 1.9B 373M
Diluted EPS 1.04 0.71 1.16 0.23
Net profit margin 28.89% 19.42% 33.40% 6.54%
Net change in cash 424M 1.5B 409M -343M
Cash on hand 7.34B 6.91B 5.41B 5B
Cost of revenue 1.84B 1.65B 1.63B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 22.56B 20.78B 19.43B 16.56B
Net income 4.92B 1.01B 4.46B 1.57B
Diluted EPS 3.01 0.61 2.65 0.93
Net profit margin 21.81% 4.85% 22.94% 9.45%
Net change in cash 1.49B 1.18B 1.85B -3.19B
Cash on hand 6.91B 5.42B 4.24B 2.39B
Cost of revenue 6.55B 6.09B 4.97B 3.91B

Financial data from company earnings reports

Financial report summary

?
Management Discussion
  • U.S. revenues increased due to higher demand for Eliquis, Opdivo and Yervoy. Average U.S. net selling prices were approximately 2% higher after discounts, charge-backs and rebates in the three months ended March 31, 2019 and are expected to be roughly flat on a full year basis.
  • Europe revenues increased due to higher demand for Opdivo and Eliquis, partially offset by unfavorable foreign exchange and lower average net selling prices.
  • Rest of the World revenues remained unchanged as higher demand for Opdivo, Eliquis and Yervoy was offset by unfavorable foreign exchange and lower demand for established brands.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: ACS, adequately, advisory, affirmed, ahead, alive, annuity, anticancer, antiplatelet, Appellate, Arabia, Asia, aspirin, asymptomatic, Athene, Autoinjector, automatic, backup, began, bench, borrowed, borrowing, breached, bridge, Burgundy, celgene, Chancery, classified, concurrently, consummation, contemporaneously, converting, correspondingly, CRC, CreditWatch, CRNM, deal, defense, depart, description, diagnosed, documentary, drawn, elotuzumab, enjoin, entry, Erbitux, ERISA, estate, evidence, exemption, expedient, exploratory, facing, failing, FCPA, flat, fluctuate, fourteenth, guarantee, guaranteed, Hawaii, hormone, HSR, immaterial, immunologic, implicit, implied, Importantly, inaccurately, indemnity, inflammatory, inhibition, injection, JNDA, jury, labor, lawsuit, lease, leased, leasehold, letter, LIBOR, master, mCRPC, Medarex, median, merged, merger, Mexico, Mutant, newly, Notably, notification, owed, partnership, PCI, Pennsylvania, permitted, pooled, Post, premium, proportion, proxy, qui, real, refinancing, regular, relationship, removed, renew, renewal, rental, restrictive, Revlimid, roughly, salesforce, Saudi, scientific, shortly, sJNDA, solicited, solution, Spending, spread, Step, storage, strength, styled, submitted, summer, supervision, Supplementary, symptomatic, syringe, tablet, tam, thirteen, tradeable, tranche, undergoing, uniQure, UPSA, Vehicle, verdict, verify, vitamin, VKA, voluntary, VTE, waiting, week, whistleblower
Removed: accelerate, achieve, adding, administered, affecting, aggregation, agile, allocate, Alpha, amendment, analyzed, antiretroviral, ASC, asunaprevir, atazanavir, atrial, Atripla, backlog, base, beclabuvir, beginning, broad, broaden, bulk, cetuximab, Chinese, choice, clarify, cobicistat, combined, commercialize, concentrated, constitute, constrained, continually, controlled, Corrupt, creating, curtailment, dabigatran, daclatasvir, deduction, demonstrated, dependent, derecognition, designed, detail, directly, disposed, distinct, docetaxel, domestic, dosing, duration, earlier, efavirenz, embolism, enacted, enactment, ending, Evotaz, exclusion, execution, exit, expensed, expire, fibrillation, force, fulfilled, funded, gap, generating, Gilead, highest, histology, identifiable, idiopathic, incomplete, infused, input, integrated, interdependent, interrelated, intravenously, introduction, invest, investigator, invoiced, irinotecan, Janssen, joint, jointly, juvenile, key, killer, lack, large, launch, legislation, leukemia, license, likelihood, limiting, manage, mandatory, mCRC, medicine, Merck, met, methotrexate, minute, monetary, natural, Nektar, network, nonfinancial, occurrence, offering, operational, organized, outlook, output, oxaliplatin, participating, pivotal, predominantly, principle, prioritized, processing, promised, prospective, protease, provisional, public, randomized, reacquired, realign, realized, receipt, reclassification, recognizing, referred, registered, released, reliably, replace, replication, requiring, resolved, reversal, reverse, rivaroxaban, schedule, SCLC, screen, selectively, separated, separation, shipment, shorter, simplify, stable, standstill, studied, substantive, sulfate, Sunvepra, syndicate, system, systemic, taxable, testing, thromboembolic, thrombotic, title, transcriptase, Tybost, typical, unbilled, untaxed, update, utilized, venture, version, voting, withholding, work, worldwide